ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 690

Assessment Of The New American and European Classification Criteria For Systemic Sclerosis In The Norwegian Systemic Connective Tissue Disease and Vasculitis Registry

Anna-Maria Hoffmann-Vold1, Torhild Garen2, Oyvind Midtvedt1 and Øyvind Molberg3, 1Rheumatology, Oslo University Hospital, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: classification criteria, diagnosis, Registries and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

Background/Purpose: To assess the newly established ACR/EULAR classification criteria for systemic sclerosis 1 (SSc) in a large Norwegian SSc registry cohort.

Methods: The Norwegian systemic connective tissue disease and vasculitis registry (NOSVAR) at the Department of Rheumatology, Oslo University Hospital (OUH) was interrogated for all systemic sclerosis (SSc) patients. All the SSc patients included in NOSVAR fulfil either the American Rheumatism Association 1980 classification criteria for SSc (ACR criteria) and/or LeRoy and Medsger’s modified criteria for the classification of early SSc. Patients are scored according to the algorithm in the new ACR/EULAR criteria and classified as SSc if scoring 9 points or more. Descriptive statistics are applied to analyse the number of patients meeting the newly established classification criteria for SSc.

Results: NOSVAR includes 381 patients with SSc. 270 SSc patients (71%) fulfil the ACR criteria. The remaining 111 SSc patients meet the modified Medsger and LeRoy criteria for SSc. The mean age at onset is 48 years (SD 0.8), the median disease duration is 10 years (range 1-48 years) and the female to male ratio is estimated to 4:1. The cohort consists of 7 limited (l) SSc patients, 277 limited cutanoeus (lc) SSc patients and 98 diffuse cutaneous (dc) SSc patients. Altogether, 73/381 patients (19%) have bilateral skin thickening extending proximal to the metacarpophalangeal (MCP) joints and are classified as SSc by this criterion alone. Of the remaining 302 patients, 296 gain >9 points by fulfilling other parameters defined in the new ACR/EULAR criteria. Only 6 patients (2%) in the NOSVAR cohort do not meet the new criteria. These 6 patients fulfil only the LeRoy and Medsger’s modified SSc criteria and have Raynauds phenomenon, pathological capillaroscopi and a positive anti-nuclear antibody, but no skin changes. 

Conclusion: This study demonstrates the applicability of the new SSc classification criteria in a large, clinical registry cohort. Only 2% of SSc patients in the cohort do not meet the new ACR/EULAR criteria.

 References

1. Van den Hoogen, F et al. Classification criteria for Systemic Sclerosis; preliminary results. Annals Rheum Dis 2013;72 (3): 59.


Disclosure:

A. M. Hoffmann-Vold,
None;

T. Garen,
None;

O. Midtvedt,
None;

Molberg,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-the-new-american-and-european-classification-criteria-for-systemic-sclerosis-in-the-norwegian-systemic-connective-tissue-disease-and-vasculitis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology